Curcumin
AntioxidantsPreclinicalAlso known as: Turmeric extract, Curcuma longa extract, Diferuloylmethane, Curcumin I, 1,7-bis-(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione, Meriva (phytosome), Theracurmin (nanoparticle), Longvida (SLCP), BCM-95 (turmeric essential oil complex), Novasol (liquid micellar), CurcuWIN, Tetrahydrocurcumin (THC, metabolite), Bisdemethoxycurcumin, Demethoxycurcumin
Curcumin is the principal bioactive polyphenol extracted from the rhizome of Curcuma longa (turmeric), constituting approximately 2-8% of dried turmeric root by weight along with two related curcuminoids (demethoxycurcumin and bisdemethoxycurcumin). The bright orange-yellow pigment has been used continuously for over 4,000 years in traditional Ayurvedic, Unani, and Siddha medicine for conditions ranging from wound healing and digestive disorders to arthritis and skin diseases, and it remains one of the most extensively studied natural compounds in modern biomedicine with over 20,000 PubMed-indexed publications and several thousand completed or ongoing clinical trials.
Overview
At A Glance
Curcumin's mechanism of action is extraordinarily pleiotropic — modulating hundreds of molecular targets across multiple pathways. While this complexity once raised "too good to be true" skepticism, thousands of mechanistic studies have established a coherent picture centered on …
Mechanism of Action
Curcumin's mechanism of action is extraordinarily pleiotropic — modulating hundreds of molecular targets across multiple pathways. While this complexity once raised "too good to be true" skepticism, thousands of mechanistic studies have established a coherent picture centered on inflammation, oxidative stress, cytokine regulation, and epigenetic modulation. NF-κB Inhibition (central mechanism): NF-κB is the master transcription factor controlling expression of hundreds of pro-inflammatory, cell-survival, and cytokine genes. Activated NF-κB drives chronic inflammation underlying atherosclerosis, arthritis, metabolic syndrome, neurodegeneration, and cancer. Curcumin inhibits NF-κB through multiple points: (1) blocking IKK (IκB kinase) phosphorylation, preventing degradation of the IκBα inhibitor; (2) directly preventing p65-p50 heterodimer nuclear translocation; (3) blocking DNA binding of the NF-κB complex at target gene promoters; (4) inhibiting upstream signals including TNF-α/TNFR1, IL-1/IL-1R, TLR2/TLR4, and RAGE pathways that activate NF-κB. Net effect: reduced transcription of TNF-α, IL-1β, IL-6, IL-8, COX-2, iNOS, VCAM-1, ICAM-1, MMP-2, MMP-9, BCL-2, BCL-XL, cyclin D1, c-myc, and dozens of other NF-κB targets. This broad transcriptional effect underlies curcumin's systemic anti-inflammatory activity. COX-2 and 5-LOX Inhibition: Cyclooxygenase-2 (COX-2) generates prostaglandins from arachidonic acid; COX-2 inhibitors (selective COXIBs, nonselective NSAIDs) are mainstay analgesics. Curcumin suppresses COX-2 both by blocking NF-κB-driven COX-2 gene transcription and by mild direct COX-2 enzyme inhibition (IC50 ~10-20 μM in vitro). 5-Lipoxygenase (5-LOX) generates leukotrienes; curcumin similarly suppresses 5-LOX expression and activity. Dual COX-2/5-LOX inhibition is pharmacologically attractive because it reduces both prostaglandin and leukotriene arms of arachidonic-acid-derived inflammation — unlike selective COX-2 inhibitors that may shunt substrate toward leukotriene production. This dual inhibition underlies curcumin's efficacy in arthritis (pain/inflammation reduction comparable to NSAIDs in OA meta-analyses). Nrf2 Activation: Nuclear factor erythroid 2-related factor 2 (Nrf2) is the master transcription factor controlling the antioxidant response element (ARE)-driven cytoprotective gene expression program. When activated, Nrf2 induces transcription of glutamate-cysteine ligase (GCLC/GCLM, rate-limiting glutathione synthesis enzymes), glutathione peroxidase, glutathione reductase, NAD(P)H:quinone oxidoreductase 1 (NQO1), heme oxygenase-1 (HO-1), superoxide dismutase, catalase, and 200+ other cytoprotective genes. Curcumin activates Nrf2 by alkylating the cysteine residues (Cys151, Cys273, Cys288) of its cytoplasmic inhibitor Keap1, releasing Nrf2 for nuclear translocation. This mechanism is shared with NAC (precursor), sulforaphane, and other "electrophilic" Nrf2 activators. Nrf2 activation produces cellular resistance to oxidative stress, xenobiotic damage, and multiple disease-relevant stressors. Cytokine Modulation: Beyond NF-κB-mediated transcriptional effects, curcumin modulates inflammatory cytokines at multiple levels. It reduces TNF-α (via NF-κB, JAK/STAT, and direct effects); IL-1β (via inflammasome inhibition — curcumin inhibits NLRP3 inflammasome activation and caspase-1 processing); IL-6 (via STAT3 pathway); IL-8 (via NF-κB). It increases anti-inflammatory cytokines IL-10 and TGF-β. Net effect is shifting the cytokine balance toward resolution. JAK-STAT Inhibition: Curcumin inhibits STAT3 (signal transducer and activator of transcription 3), a key pro-inflammatory and oncogenic transcription factor activated by IL-6 and other cytokines. STAT3 inhibition is clinically relevant because STAT3 is chronically activated in many cancers and inflammatory diseases; curcumin's STAT3 inhibition is shared with JAK inhibitors (tofacitinib, baricitinib) used in rheumatoid arthritis but with a very different safety profile. PPAR-γ Agonism: Peroxisome proliferator-activated receptor gamma (PPAR-γ) regulates adipocyte differentiation, insulin sensitivity, and anti-inflammatory effects. Curcumin is a PPAR-γ agonist (weaker than thiazolidinediones like pioglitazone but without the weight-gain/edema/heart-failure concerns). PPAR-γ activation contributes to curcumin's metabolic effects: improved insulin sensitivity, reduced hepatic steatosis, favorable adipokine profile (increased adiponectin, decreased leptin resistance), and adipose anti-inflammation. AMPK Activation: Curcumin activates AMP-activated protein kinase (AMPK), the cellular energy sensor that promotes glucose uptake, fatty acid oxidation, mitochondrial biogenesis, and autophagy. AMPK activation is shared with metformin, berberine, and caloric restriction. This mechanism underlies curcumin's metabolic benefits (improved glucose tolerance, reduced hepatic fat, improved lipid profiles). mTOR Pathway Modulation: Curcumin inhibits mTORC1 signaling (directly and via AMPK/TSC2/Rheb), producing pro-autophagy effects. This mechanism is shared with rapamycin and contributes to curcumin's potential longevity effects. Mitochondrial Effects: Curcumin has complex mitochondrial effects — at low doses it supports mitochondrial biogenesis via PGC-1α upregulation and improves mitochondrial function; at higher doses (particularly in cancer cell contexts) it induces mitochondrial membrane permeabilization, cytochrome c release, and apoptosis. In normal cells, physiologic curcumin concentrations favor protective mitochondrial effects. Epigenetic Modulation: Curcumin modulates DNA methylation (inhibits DNMT1, DNMT3b), histone modifications (inhibits class I HDACs, inhibits p300/CBP histone acetyltransferase), and microRNA expression (upregulates tumor-suppressor miRNAs like miR-34a, miR-22, miR-15a/16; downregulates oncogenic miRNAs). These epigenetic effects may underlie some long-term benefits of chronic curcumin exposure. Amyloid and Tau Effects: Curcumin binds directly to amyloid-β (Aβ) fibrils (demonstrated by Yang 2005 PMID 15590663), inhibits Aβ aggregation, and may promote Aβ clearance by microglia. It also inhibits tau protein aggregation. These effects underlie research interest in curcumin for Alzheimer disease, though clinical translation has been limited by bioavailability and translation from preclinical models. Longvida formulation (which penetrates the BBB measurably) and Theracurmin have been used in AD/MCI trials with some positive signals (Small 2018). Angiogenesis Inhibition: Curcumin inhibits angiogenesis through reduction of VEGF expression (via HIF-1α suppression), inhibition of endothelial cell proliferation, and suppression of bFGF. This is relevant to cancer (angiogenesis inhibition is a validated anticancer strategy) and diabetic retinopathy. Gut Microbiome Effects: Recent research (Peterson 2018 and others) shows that curcumin modulates gut microbiome composition favorably: increasing Bifidobacterium, Lactobacillus, Faecalibacterium prausnitzii (butyrate-producer); reducing pathobiont proportions including Enterobacteriaceae and certain Clostridial species. Microbiome-mediated effects contribute to both systemic inflammation and metabolic regulation and may represent a significant mechanism given the poor systemic bioavailability of curcumin (most dose remains in gut lumen where it can affect microbiome). Iron Chelation: Curcumin chelates iron through its beta-diketone moiety. This is relevant both as a mechanism (reducing iron-catalyzed free radical generation via Fenton chemistry) and as a safety consideration (theoretical concern about iron deficiency with chronic high-dose curcumin, though clinical evidence of this is limited). P-Glycoprotein Interaction: Curcumin is a substrate of P-glycoprotein (P-gp/MDR1) efflux transporter in the gut, which contributes to its poor systemic bioavailability. Curcumin is also a P-gp inhibitor, raising both benefit (potential to overcome multidrug resistance in cancer cells) and safety concerns (potential drug-drug interactions with other P-gp substrates including many medications). CYP Interactions: Curcumin inhibits CYP3A4, CYP1A2, CYP2D6, and CYP2C9 in vitro. Clinical relevance varies — for most drug interactions the effects are modest but may be significant for narrow-therapeutic-index drugs like warfarin, tacrolimus, cyclosporine, and certain chemotherapeutics. Tetrahydrocurcumin (THC) Metabolism: Curcumin is metabolized in the gut and liver to tetrahydrocurcumin (THC) and hexahydrocurcumin. THC retains much of curcumin's antioxidant and anti-inflammatory activity and may be a major active circulating species, particularly after oral dosing. THC is more water-soluble than curcumin and has superior pharmacokinetics. Some supplement formulations now provide THC directly. Pharmacokinetic Limitations: Standard curcumin (95% curcuminoids extract) has very poor oral bioavailability due to: poor water solubility (~11 ng/mL); rapid degradation at neutral-to-alkaline pH; extensive glucuronidation/sulfation (phase II metabolism) in gut wall and liver; active P-gp efflux in intestine; first-pass metabolism. Peak free curcumin plasma concentrations after standard 8 g doses are barely detectable (<50 ng/mL). This poor PK has been addressed by advanced formulations (Meriva: ~29-fold increase; Theracurmin: ~27-fold; BCM-95: ~7-fold; Longvida SLCP: ~65-100-fold; Novasol: ~185-fold) that represent the modern state of curcumin delivery. Many clinical trials have used these enhanced formulations; results from trials using standard curcumin should be interpreted with this limitation in mind.
Overview
Curcumin is the principal bioactive polyphenol extracted from the rhizome of Curcuma longa (turmeric), constituting approximately 2-8% of dried turmeric root by weight along with two related curcuminoids (demethoxycurcumin and bisdemethoxycurcumin). The bright orange-yellow pigment has been used continuously for over 4,000 years in traditional Ayurvedic, Unani, and Siddha medicine for conditions ranging from wound healing and digestive disorders to arthritis and skin diseases, and it remains one of the most extensively studied natural compounds in modern biomedicine with over 20,000 PubMed-indexed publications and several thousand completed or ongoing clinical trials. Chemically, curcumin is a symmetric diferuloylmethane molecule (1,7-bis-(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione) with an enolized beta-diketone bridge between two aromatic rings bearing phenolic hydroxyl groups — this structure underlies both its antioxidant/electrophile-scavenging activity and its chemical instability. Curcumin degrades rapidly in neutral-to-alkaline aqueous conditions (half-life of minutes at physiological pH), is extensively conjugated to glucuronides and sulfates by phase II enzymes in the gut wall and liver, undergoes reductive metabolism to tetrahydrocurcumin and hexahydrocurcumin by gut bacteria and hepatic reductases, and is actively effluxed by intestinal P-glycoprotein. The net consequence of this unfavorable pharmacokinetic profile is that standard 95% curcuminoid extracts produce barely detectable free curcumin in plasma after oral dosing — a fact that invalidated much of the early curcumin research and delayed clinical translation for decades. The bioavailability problem has been addressed over the past 15 years through a generation of advanced delivery formulations that represent a genuine pharmaceutical advance rather than marketing: Meriva (Indena phytosome technology) complexes curcumin with soy or sunflower phosphatidylcholine, producing 29-fold increased bioavailability and strong clinical evidence in osteoarthritis (Belcaro 2010 PMID 21194249); Theracurmin (Theravalues nanoparticle dispersion) achieves 27-fold bioavailability increase and is the form used in the landmark Small 2018 cognitive aging trial; Longvida (Verdure Sciences solid-lipid curcumin particles) produces 65-100 fold increase and crosses the blood-brain barrier measurably; BCM-95 (Arjuna Natural turmeric essential oil complex) provides 7-fold increase; Novasol (liquid micellar) reaches 185-fold bioavailability in pharmacokinetic studies. These formulations have converted curcumin from a bench-science curiosity to a legitimate therapeutic with outcome trials supporting use in osteoarthritis, non-alcoholic fatty liver disease, metabolic syndrome, depression, cognitive aging, inflammatory bowel disease, and radiation dermatitis prevention. Clinical evidence is strongest for: Osteoarthritis (Daily 2016 meta-analysis PMID 27533649 pooled 8 RCTs showing effects comparable to NSAIDs for knee OA pain and function; Belcaro 2010 Meriva knee OA; Kuptniratsaikul 2014 PMID 24672232 head-to-head vs ibuprofen for knee OA showing non-inferiority); NAFLD/fatty liver (Rahmani 2016 demonstrated ultrasound resolution of hepatic steatosis; Panahi 2017 meta-analysis); Metabolic syndrome and type 2 diabetes (Chuengsamarn 2012 PMID 22773702 showed 9-month curcumin prevented T2D conversion in 16% of prediabetics vs placebo; Na 2014 meta-analysis); Depression (Sanmukhani 2014 randomized trial showing efficacy comparable to fluoxetine; Ng 2017 meta-analysis PMID 28236605); Cognitive aging (Small 2018 18-month Theracurmin trial showing memory and attention benefits plus reduced amyloid/tau on PET imaging); Radiation dermatitis prevention (Ryan 2013 breast cancer radiation therapy). Evidence is weaker or negative for: curcumin as standalone cancer therapy (despite extensive preclinical data, large clinical trials have not demonstrated meaningful oncologic benefit); Alzheimer disease treatment (Ringman 2012 24-week trial was negative for cognition despite biomarker effects); long-term prevention endpoints (most trials are <12 months). The molecule's truly exceptional feature is its pleiotropy — curcumin modulates hundreds of molecular targets across inflammation, oxidative stress, mitochondrial function, apoptosis, angiogenesis, epigenetic regulation, and gut microbiome composition. Principal mechanisms include direct inhibition of NF-κB nuclear translocation (the master inflammatory transcription factor); suppression of COX-2 and 5-LOX (the enzymes inhibited respectively by NSAIDs and leukotriene-receptor antagonists); activation of Nrf2 (the master antioxidant transcription factor that induces HO-1, NQO1, glutathione-synthesis enzymes, and other cytoprotective genes); reduction of TNF-α, IL-1β, IL-6, and other pro-inflammatory cytokines; modulation of STAT3, AP-1, β-catenin, and other oncologically-relevant transcription factors; PPAR-γ agonism relevant to adipose and metabolic function; and emerging evidence for favorable gut microbiome modulation (increasing Bifidobacterium and Lactobacillus, reducing pathobiont proportions). Safety is exceptional: curcumin has a GRAS (Generally Recognized As Safe) designation from the FDA, has been used as a food spice in Indian cuisine at gram-level daily intakes for millennia without population-level toxicity signals, and has a clean safety profile in clinical trials up to 8 g/day for extended periods. The main practical safety considerations are drug interactions (CYP3A4 and P-glycoprotein substrate implications; warfarin INR effects), gallstone or bile-duct obstruction (curcumin stimulates bile flow and could theoretically worsen), and coordination with oncology during active chemotherapy. This entry covers curcumin's pharmacology, the bioavailability problem and formulation solutions, mechanism of action across inflammation/metabolism/neurobiology, the clinical evidence base by indication, drug interactions and safety, formulation selection for different goals, and integration with other evidence-based compounds including NAC, CoQ10, berberine, NMN, rapamycin, and glutathione.
Chemical Information
IUPAC Name
Not yet available
CAS Number
Not yet available
Molecular Formula
Not yet available
Molecular Mass
Not yet available
Chemical data is being compiled for this compound.
Dosing & Protocols
Unlock Dosing Protocols
Free account gets you:
- View beginner, intermediate & advanced protocols
- See weight-based dosing calculations
- Access cycle length & frequency data
2,800+ researchers already in
Research
Unlock Research Data
Free account gets you:
- Browse PubMed study summaries
- See clinical trial phases & results
- Access mechanism of action details
2,800+ researchers already in
Interactions
Contraindications
Curcumin has few absolute contraindications but multiple relative contraindications and drug interactions warranting awareness. Absolute Contraindications: Known hypersensitivity to curcumin, turmeric, or formulation excipients (rare but reported). Relative Contraindications and Cautions: Gallbladder disease (gallstones, cholelithiasis, cholecystitis): Curcumin stimulates gallbladder contraction and bile flow. Theoretically can worsen symptoms of existing gallstones or trigger gallstone-related biliary colic. Patients with known gallstones: discuss with gastroenterology before supplementation; low-dose or enhanced formulation with lower curcumin delivery may be more tolerable. Patients with prior cholecystectomy: generally acceptable. Bile duct obstruction: Contraindicated; do not use. Active peptic ulcer disease: Relative contraindication due to curcumin's mild gastric mucosal effects; can be used with caution after ulcer healing. Hemochromatosis or iron overload: Curcumin's iron-chelating properties are generally beneficial in iron overload. However, consider dose implications and discuss with hematology. Iron deficiency anemia: Relative concern given iron chelation. Avoid high doses; separate timing from iron supplementation by 2-4 hours. Monitor iron status. Kidney stones (oxalate): Theoretical concern; turmeric contains oxalates; evidence for curcumin supplements causing stones is limited. Active bleeding or bleeding disorders: Relative contraindication due to antiplatelet activity. Scheduled surgery: Discontinue 2 weeks before elective procedures. Pregnancy: Traditional cautions about uterotonic effects. Dietary turmeric is safe. High-dose curcumin supplementation not recommended during pregnancy except under specialist supervision. Breastfeeding: Dietary turmeric acceptable; supplementation safety data limited, generally avoid high-dose supplementation. Pediatric Use: Dietary turmeric safe. High-dose therapeutic supplementation only under pediatric physician supervision for specific indications. Major Drug Interactions: Warfarin: Clinically significant interaction. Curcumin inhibits CYP2C9 (warfarin metabolism) and has mild antiplatelet activity. Combination can elevate INR. Management: Monitor INR weekly for 2-4 weeks when initiating or changing curcumin dose in warfarin patients. Warfarin dose may need reduction (typically 10-20%). Always inform anticoagulation clinic about curcumin. DOACs (apixaban, rivaroxaban, dabigatran, edoxaban): Potential increased effect via P-gp inhibition (particularly with high-dose curcumin or piperine-enhanced formulations). Clinical significance uncertain. Monitor for bleeding. Antiplatelet agents (aspirin, clopidogrel, prasugrel, ticagrelor): Additive antiplatelet effect; combination generally safe but increase bleeding monitoring vigilance. Chemotherapy agents: Complex and agent-specific. Curcumin may inhibit CYP3A4 (metabolism of many oncology drugs). May affect P-gp-dependent efflux. Some evidence of synergy with specific agents; some evidence of antagonism. Management: Discuss with oncology before combining with active chemotherapy. Treatment decisions should involve medical oncologist. Immunosuppressants (tacrolimus, cyclosporine, everolimus, sirolimus): Curcumin's CYP3A4 and P-gp inhibition can increase immunosuppressant exposure. Important for transplant patients and autoimmune disease management. Monitor drug levels and adjust as needed. Statins (atorvastatin, simvastatin, lovastatin — CYP3A4-metabolized): Potential modest increase in statin exposure. Rosuvastatin, pravastatin less affected (different metabolism). Clinical significance usually modest but theoretical myopathy concern with high-dose combinations. Calcium channel blockers (amlodipine, diltiazem, verapamil): CYP3A4-metabolized; potential modest interaction. Benzodiazepines (alprazolam, midazolam, triazolam): CYP3A4-metabolized; potential interaction; generally not clinically significant. Acetaminophen (paracetamol): Minimal interaction at normal doses. NSAIDs: Additive antiplatelet/GI effects; generally safe; may allow lower NSAID doses in OA/RA. Corticosteroids: Complementary anti-inflammatory; may allow lower corticosteroid doses in inflammatory conditions. Antidepressants (SSRIs, SNRIs, TCAs, MAOIs): Generally compatible. Curcumin has own antidepressant effects; combination can be additive. Monitor for serotonergic effects with SSRIs/SNRIs (theoretical but rare clinical significance). Diabetes medications (insulin, sulfonylureas, metformin, GLP-1 agonists, SGLT2 inhibitors): Additive glucose-lowering. Monitor blood glucose. Dose adjustment of antidiabetic agents may be needed. Particular attention in brittle diabetes. Thyroid hormone (levothyroxine): Possible GI absorption interference. Separate dosing by 4 hours to optimize thyroid hormone absorption. Iron supplements: Curcumin chelates iron. Separate timing by 2-4 hours. H2 blockers and PPIs: Minimal interaction. Antibiotics: Generally compatible; some theoretical interaction with specific fluoroquinolones via chelation; separate timing when feasible. Oral contraceptives and hormone replacement therapy: Generally compatible; minimal interaction. Herbal Interactions: Ginger: Additive antiplatelet; generally compatible. Ginkgo biloba: Additive antiplatelet; monitor. Garlic (high-dose): Additive antiplatelet; monitor. St. John's Wort: Opposite CYP3A4 effects (curcumin inhibits, St. John's Wort induces); complex interaction. Green tea extract: Generally compatible; complementary. Kava: Both have hepatic considerations; avoid combination. Reishi, cordyceps, other mushrooms: Generally compatible. Alcohol: Moderate alcohol acceptable. Heavy alcohol compounds any GI irritation and may increase hepatic metabolism demands. Caffeine: Minimal interaction. Tobacco: Not a direct interaction but tobacco use increases inflammation that curcumin opposes; benefits of curcumin diminished in smokers. Cannabis: Generally compatible; no established significant interaction. Laboratory Test Effects: Curcumin can affect some laboratory tests via pigment interference or actual physiologic effects. Report curcumin use when having unusual lab results. Surgical Considerations: Discontinue 2 weeks before elective surgery due to antiplatelet activity. Emergency surgery: inform surgical team. Resume curcumin 2 weeks post-surgery when wound healing is established and bleeding risk is minimal. Organ Impairment: Hepatic impairment: Moderate: reduce dose 50%; monitor LFTs. Severe: avoid until liver function stabilizes. Note: curcumin generally improves rather than impairs liver function based on clinical evidence; the caution relates to reduced metabolism capacity, not hepatotoxicity from curcumin itself. Renal impairment: Limited data in severe CKD. Generally considered acceptable. Dose adjustment not typically needed. Cardiac impairment: Generally safe. Monitor for bleeding when on anticoagulants. Special Populations: Elderly (>75): Generally compatible; watch for drug interactions given typically higher medication burden. Frail elderly: Start lower doses; monitor for GI tolerability. Pregnancy: See above — dietary turmeric safe; avoid high-dose supplementation. Breastfeeding: Dietary turmeric safe; avoid high-dose supplementation. Children: Therapeutic use only under pediatric supervision. Transplant recipients: Immunosuppressant interactions; consult transplant team. Active cancer patients: Oncology coordination essential. Autoimmune disease: Generally beneficial; may allow reduced immunosuppressant doses. Psychiatric conditions: Compatible with psychiatric medications. Symptoms Warranting Medical Attention: Unusual bleeding or bruising (particularly on anticoagulants); abdominal pain (particularly RUQ pain suggesting gallbladder); severe GI symptoms (vomiting, severe diarrhea, severe pain); significant LFT elevation; allergic reactions (rash, itching, facial swelling, breathing difficulty); unexpected changes in medication effect (INR changes, diabetes control, BP); yellow eye sclera (may indicate liver issue — though curcumin yellow staining of stool is normal and expected). Regulatory Status: Dietary supplement in US, Canada, EU, UK, Australia, Japan, and most countries. GRAS status for food use. Not a prescription medication in any major jurisdiction. Quality and Authenticity: Critical concern. Counterfeiting, adulteration (lead chromate in cheap turmeric), and variable quality are documented problems. Choose reputable brands with third-party testing. Overdose: Acute massive overdose has not been reported as clinically harmful. Expected features: severe GI symptoms, yellow-orange staining, potential mild hepatic effects. Supportive management. No specific antidote needed. Discontinuation: No withdrawal effects. Tissue effects resolve over weeks post-discontinuation. Multi-Supplement Users: Curcumin integrates well with most supplement regimens. Aware of additive effects with other anti-inflammatory/antiplatelet supplements (omega-3, ginger, garlic, ginkgo). Assessment Summary: Curcumin is safe for most adults with attention to drug interactions (particularly anticoagulants, chemotherapy, immunosuppressants), bleeding risk considerations, and product quality. The pleiotropic mechanism creates numerous potential interactions, most of which are minor but require awareness. For patients with complex medication regimens, review with pharmacist or physician familiar with nutritional medicine is valuable.
Research Disclaimer
This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds.
No listings found for Curcumin.
Related Compounds
View AllSide-by-Side Comparisons
All ComparisonsView Full Dosage Guide →
Protocols, calculator & safety for Curcumin
Research Score
2 PubMed studies
Quality Indicators
Data Completeness
63%Research Credibility
Limited research available
Quick Facts
Trial Phase
Preclinical
Research Disclaimer
This information is for educational and research purposes only. Not intended as medical advice. Consult a healthcare professional before use.
Frequently Asked Questions
What's the best curcumin formulation?
The 'best' depends on intended use and budget. For osteoarthritis: Meriva (phytosome) has strongest OA evidence; Belcaro 2010 (PMID 21194249) established Meriva 1000 mg/day for knee OA. Cost: ~$30/month. For cognitive aging: Theracurmin 180 mg/day has Small 2018 (PMID 29204412) evidence for memory/attention benefits; Longvida 400 mg/day has measurable BBB penetration. Cost: ~$40-60/month. For NAFLD/metabolic: Amorphous dispersion or phytosome 500 mg/day. For depression: BCM-95 500 mg BID has Sanmukhani 2014 (PMID 24259463) evidence. For general wellness/budget: 95% curcuminoids + piperine (BioPerine) 500 mg/day. Cost: ~$15-20/month. Formulation technologies explained: Meriva uses phytosome technology (curcumin bonded to phosphatidylcholine); Theracurmin uses nanoparticle dispersion; Longvida uses solid-lipid curcumin particles; BCM-95 combines curcuminoids with turmeric essential oil (ar-turmerone); Novasol uses liquid micellar delivery; CurcuWIN uses patented dispersion. Bioavailability multipliers vs. standard: Meriva ~29x, Theracurmin ~27x, BCM-95 ~7x, Longvida ~65-100x, Novasol ~185x. Important: Bioavailability multipliers don't translate directly to clinical effect size; formulation choice should also consider published clinical trial evidence for the specific formulation and indication. For most therapeutic uses, an evidence-supported enhanced formulation is better value than standard 95% curcuminoids despite higher cost.
Does curcumin with piperine really work better?
Yes — piperine (from black pepper, often as BioPerine 95%+ standardized) dramatically enhances curcumin bioavailability. Shoba 1998 (PMID 9619120) demonstrated 2000% (20-fold) increase in curcumin bioavailability with piperine 20 mg added to curcumin 2 g. Mechanism: piperine inhibits intestinal UDP-glucuronosyltransferase (blocking first-pass glucuronidation) and P-glycoprotein efflux. Practical implications: Curcumin + piperine is a cost-effective bioavailability enhancement that makes standard 95% curcuminoids substantially more effective. Typical products contain 500 mg curcumin + 5-10 mg BioPerine. Caveats: Piperine also inhibits CYP3A4 and P-gp for OTHER drugs, creating drug interaction potential. For patients on medications metabolized through CYP3A4 (statins, calcium channel blockers, benzodiazepines, some antidepressants, immunosuppressants, chemotherapy agents), piperine-enhanced curcumin may cause clinically significant drug interactions. Alternative bioavailability strategies (Meriva, Theracurmin, Longvida, BCM-95, Novasol) achieve enhanced curcumin delivery WITHOUT piperine, avoiding the drug interaction issue. For simple users on minimal medications, piperine-enhanced curcumin is economical and effective. For users on complex medication regimens, piperine-free enhanced formulations are safer choice.
Is curcumin safe for long-term daily use?
Yes — curcumin has an excellent long-term safety profile based on multiple decades of clinical use and centuries of dietary turmeric consumption in Indian cuisine (where daily intake can reach grams). Clinical trials have safely used curcumin at doses up to 8-12 g/day for weeks-to-months and 500-2000 mg/day for 12+ months without significant toxicity. Multi-year continuous use at 500-1000 mg/day of enhanced formulation is safe based on available evidence. Practical safety considerations for long-term use: (1) Choose high-quality product with third-party testing to avoid heavy metal contamination; (2) Periodic lab monitoring (annual CMP for liver function, CBC) is reasonable but not strictly necessary for most users; (3) Be aware of drug interactions if new medications are added; (4) Discontinue 2 weeks before elective surgery; (5) Coordinate with oncology during any cancer treatment. Populations with specific long-term safety considerations: patients with gallbladder disease, bleeding disorders, iron deficiency anemia, or on anticoagulants/chemotherapy/immunosuppressants — discuss with healthcare provider before chronic use. Rare hepatotoxicity reports: Most attributable to specific adulterated or contaminated products rather than pure high-quality curcumin. Occasional case reports in patients with underlying liver disease or on specific drug combinations. Pure curcumin from reputable manufacturers has excellent liver safety and may actually improve liver function (NAFLD evidence). Population scale: Turmeric has been consumed daily in gram amounts by billions of people across India, Southeast Asia, and increasingly globally for millennia without population-level toxicity signals — strong real-world safety evidence. Bottom line: Curcumin at 500-2000 mg/day of appropriate formulation is one of the safer long-term daily supplements available.
Can curcumin replace NSAIDs for arthritis pain?
For many patients with mild-to-moderate osteoarthritis, yes — curcumin can reduce or replace NSAID use. The evidence base: Daily 2016 meta-analysis (PMID 27533649) pooled 8 RCTs showing curcumin reduces pain and improves function in knee OA with effect sizes comparable to NSAIDs. Kuptniratsaikul 2014 (PMID 24672232) randomized 367 knee OA patients directly to curcumin 1.5 g/day versus ibuprofen 1.2 g/day for 4 weeks, finding curcumin NON-INFERIOR for pain and function with superior GI tolerability. Belcaro 2010 (PMID 21194249) demonstrated Meriva 1 g/day produced significant WOMAC improvements and reduced NSAID use by 63% in knee OA patients. Practical approach: For mild-moderate knee or hip OA, a reasonable strategy is: (1) Start curcumin (Meriva 1 g/day or BCM-95 500 mg BID) and continue for 8-12 weeks; (2) During curcumin trial, use NSAIDs as needed for breakthrough pain; (3) After 8-12 weeks of curcumin loading, attempt to reduce or discontinue NSAIDs; (4) Many patients achieve substantial NSAID reduction or elimination. Advantages over NSAIDs: No GI bleeding risk, no renal toxicity, no cardiovascular risk concerns, safer for older patients with multiple comorbidities, safer for chronic daily use. Limitations: Slower onset of effect (curcumin takes weeks; NSAIDs take hours); less potent for acute severe pain; not effective for all OA patients. For inflammatory arthritis (RA, psoriatic, ankylosing spondylitis): Curcumin is adjunct not replacement; biologics and DMARDs remain cornerstone. Curcumin can reduce symptomatic burden and potentially allow lower DMARD doses under rheumatology supervision. Bottom line: For OA, curcumin is a legitimate alternative or complement to NSAIDs with favorable safety profile. For inflammatory arthritis, curcumin is adjunct to standard therapy.
Does curcumin help with depression?
Yes — curcumin has meaningful evidence for mild-moderate depression, supporting use as adjunct to or alternative to prescription antidepressants. Key evidence: Sanmukhani 2014 (PMID 24259463) randomized 60 MDD patients to curcumin 1 g/day, fluoxetine 20 mg/day, or combination for 6 weeks, finding curcumin non-inferior to fluoxetine. Lopresti 2014 (PMID 24871396) randomized 56 depressed patients to curcumin 1 g/day or placebo for 8 weeks, finding significant depression reduction in curcumin group. Ng 2017 meta-analysis (PMID 28236605) pooled 6 RCTs (377 total patients) confirming antidepressant efficacy. Mechanism: Multiple pathways including monoamine modulation (mild MAO inhibition; increased serotonin, dopamine, norepinephrine), BDNF upregulation, reduction of neuroinflammation (which is increasingly implicated in depression pathophysiology), HPA axis modulation, and antioxidant effects. Practical dosing: BCM-95 500 mg BID (as used in Sanmukhani 2014) or enhanced formulation equivalent (Meriva 1000 mg/day, Theracurmin 180 mg/day, or 1000 mg/day 95% curcuminoids + piperine). Trial for 6-8 weeks to assess response. Best use cases: Mild-moderate depression, depression with inflammatory features (elevated CRP), depression with atypical features, depression concurrent with other inflammatory conditions (OA, metabolic syndrome). Can be combined with prescription antidepressants: Generally compatible with SSRIs, SNRIs, TCAs, bupropion, mirtazapine. Monitor for additive effects. Not a substitute for: Acute suicidal depression (pharmacologic treatment with psychiatric care); severe refractory depression (requires comprehensive psychiatric management); bipolar depression (risk of mood instability with any antidepressant). Lifestyle integration: Curcumin's antidepressant effects are best realized alongside comprehensive depression management: exercise, adequate sleep, social connection, cognitive behavioral approaches, reduction of alcohol/substance use. Bottom line: Reasonable adjunct or alternative for mild-moderate depression; not replacement for comprehensive psychiatric care in severe cases.
Can curcumin cross the blood-brain barrier to help with Alzheimer disease?
Standard curcumin crosses the BBB poorly; enhanced formulations (particularly Longvida, which uses solid-lipid curcumin particles) cross measurably. Alzheimer clinical evidence is mixed. Key trials: Ringman 2012 (PMID 22818031) randomized 36 mild-moderate AD patients to standard curcumin 2-4 g/day or placebo for 24 weeks, finding NO cognitive benefit. This trial used non-enhanced curcumin with expected poor BBB penetration. Baum 2008 (PMID 19110202) Hong Kong AD trial was similarly negative. Small 2018 (PMID 29204412) — importantly, in cognitively normal adults with subjective memory impairment (not established AD) — used Theracurmin 180 mg/day for 18 months and found significant memory/attention improvements PLUS reduced amyloid/tau on PET imaging. This is the most positive human evidence. Preclinical evidence for AD: Extensive. Curcumin binds amyloid-β, inhibits amyloid aggregation, promotes microglial clearance of amyloid, inhibits tau hyperphosphorylation, reduces neuroinflammation. Discrepancy between preclinical promise and human trial results: Attributable to (1) poor BBB penetration of standard formulations used in most trials; (2) disease stage — curcumin may be more effective for prevention/early intervention than established AD; (3) short trial durations relative to the slow AD process. Current reasonable approach: For cognitive aging or MCI, Theracurmin 180 mg/day or Longvida 400 mg/day for 12-18+ months is supported by Small 2018 evidence. Combine with omega-3 high-DHA 2 g/day, Mediterranean/MIND diet, aerobic exercise, cognitive engagement, sleep optimization, vitamin D, and B-complex. For established AD: Curcumin may have modest role as adjunct but is NOT disease-modifying treatment. Standard AD management (cholinesterase inhibitors, memantine, aducanumab/lecanemab per specialist) remains primary. Realistic expectations: Curcumin is one component of multifactorial brain-health approach; not a single-molecule cure for dementia. Prevention/early intervention framework more relevant than treatment of established disease.
Does curcumin interact with medications?
Yes, more than many supplements — curcumin has significant drug interaction potential that requires awareness. Most significant interactions: Warfarin: Curcumin inhibits CYP2C9 (warfarin metabolism) and has mild antiplatelet activity. Can elevate INR. Monitor INR weekly for 2-4 weeks when initiating or changing curcumin dose. Warfarin dose may need reduction. Chemotherapy agents: Complex and agent-specific. Curcumin may inhibit CYP3A4 metabolism of many oncology drugs; may affect P-gp-mediated drug efflux; theoretical antagonism with pro-oxidant agents. Always coordinate with oncology. Immunosuppressants (tacrolimus, cyclosporine, sirolimus, everolimus): Curcumin's CYP3A4/P-gp inhibition can increase exposure. Important for transplant recipients. Monitor drug levels. DOACs (apixaban, rivaroxaban, dabigatran): Potential increased exposure via P-gp inhibition; monitor for bleeding. Antiplatelets (aspirin, clopidogrel, ticagrelor): Additive antiplatelet effect; monitor for bleeding but rarely clinically significant. Statins (atorvastatin, simvastatin, lovastatin — CYP3A4 metabolized): Modest increase in exposure; theoretical myopathy concern at high-dose combinations; usually not clinically significant. Diabetes medications (insulin, sulfonylureas, metformin): Additive glucose-lowering; monitor blood glucose; may allow reduced antidiabetic doses. Thyroid hormone: Possible absorption interference; separate by 4 hours. Iron supplements: Chelation; separate by 2-4 hours. Piperine considerations: If curcumin is piperine-enhanced (as in many OTC formulations), piperine itself inhibits CYP3A4 and P-gp for MANY other drugs, adding to interaction profile. Piperine-free enhanced formulations (Meriva, Theracurmin, Longvida, Novasol) avoid this additional layer of interactions. Practical approach: (1) Inform all healthcare providers about curcumin use; (2) Pharmacist review for patients on complex medication regimens; (3) Monitor specific drugs with narrow therapeutic index (warfarin INR, tacrolimus level, etc.); (4) Preferential use of non-piperine enhanced formulations for patients on multiple medications; (5) Always coordinate with oncology for chemotherapy patients. Generally compatible: Most antihypertensives, antidepressants, NSAIDs, acetaminophen, H2 blockers, PPIs, hormone replacement therapy, oral contraceptives, antibiotics (with separation timing for iron/tetracycline class).
Does curcumin lower blood sugar and help with diabetes?
Yes — curcumin has meaningful evidence for glucose regulation and diabetes prevention. Landmark trial: Chuengsamarn 2012 (PMID 22773702) randomized 240 prediabetic adults to curcumin 1.5 g/day (6 capsules of 250 mg curcuminoid extract) or placebo for 9 months. Results: 16.4% of placebo group progressed to type 2 diabetes versus 0% in curcumin group — a statistically significant (P<0.001) primary endpoint, remarkable for any supplement intervention. Secondary endpoints: improved HOMA-IR (insulin sensitivity), improved HOMA-β (beta cell function), improved lipid profile. For established T2D: Na 2014 meta-analysis (PMID 24293002) pooled 5 RCTs finding curcumin reduced HbA1c (modest effect) and fasting glucose. Other meta-analyses (Panahi 2017) confirmed glycemic benefits. Mechanisms: (1) AMPK activation (shared with metformin and berberine) — improves glucose uptake and fatty acid oxidation; (2) PPAR-γ agonism — improves insulin sensitivity; (3) Reduced inflammation (NF-κB inhibition, TNF-α/IL-6 suppression) — reverses inflammation-mediated insulin resistance; (4) Direct effects on beta cell function; (5) Favorable gut microbiome modulation affecting glycemic regulation. Practical approach: For prediabetes/T2D prevention: 1500 mg/day standard extract (Chuengsamarn protocol) or enhanced formulation equivalent (Meriva 1500 mg or Theracurmin 180 mg BID). Continue for 6-12 months minimum. For established T2D: Adjunct to standard management (metformin, lifestyle intervention, other agents per guidelines). Curcumin 500-1000 mg/day enhanced formulation. Monitor glucose to catch any additive hypoglycemic effect. Combinations: Curcumin + berberine (both AMPK activators; synergistic); curcumin + metformin; curcumin + NAC; curcumin + alpha-lipoic acid; curcumin + chromium. Lifestyle integration: Curcumin's glucose-lowering effects are maximized with diet (reduced refined carbohydrates, adequate protein, Mediterranean pattern), regular physical activity, weight management, adequate sleep, stress management. Safety note: Curcumin's additive glucose-lowering effect with antidiabetic medications can occasionally cause hypoglycemia. Monitor glucose when initiating curcumin in patients on insulin or sulfonylureas. Bottom line: Curcumin is a legitimate evidence-supported intervention for diabetes prevention and management, with the Chuengsamarn trial providing rare high-quality evidence for diabetes prevention from a supplement.
Can I just use turmeric powder from my spice cabinet instead of curcumin supplements?
For cooking flavor, yes. For therapeutic effect, generally no — the bioavailability is too poor. Here's why: Curcuminoid content: Dried turmeric root is 2-8% curcuminoids by weight. To match a therapeutic curcumin dose of 500 mg, you'd need approximately 10-25 grams of turmeric powder daily (2-5 teaspoons) — far more than typical culinary use. Bioavailability: Curcumin from turmeric powder has extremely poor oral absorption — estimated systemic bioavailability <1% for standard powder. Enhanced formulations (Meriva, Theracurmin, Longvida) achieve 7-185× better absorption. Degradation in cooking: Curcumin degrades with heat and alkaline conditions. High-temperature cooking (grilling, frying) substantially reduces curcumin content of the final dish. Comparison: 1 teaspoon turmeric powder (2-3 g) contains approximately 50-100 mg curcuminoids. Of that, perhaps 1-5 mg achieves systemic absorption. Compare to Meriva 1000 mg delivering 200 mg curcumin at 29-fold bioavailability = approximately 200-400 mg effective dose equivalent. What turmeric powder IS good for: (1) Culinary use — flavor, color, and some gut-local effects; (2) Traditional Ayurvedic paste/topical applications; (3) Anti-inflammatory effects on gut lumen that don't require systemic absorption (some IBD-relevant effects); (4) General wellness in the context of an anti-inflammatory diet pattern. What turmeric powder CANNOT reliably do: (1) Therapeutic systemic anti-inflammatory effect; (2) Joint pain relief at doses tested in OA trials; (3) Metabolic/cardiovascular outcomes in clinical trials; (4) CNS effects for depression or cognition. Optimization strategies for culinary turmeric: Adding black pepper (piperine) to turmeric dishes enhances absorption (though still far below enhanced supplement formulations); combining with fat (ghee, coconut oil, olive oil) improves lipophilic absorption; "golden milk" combining turmeric + fat + black pepper + heat is a somewhat-bioavailable preparation. Bottom line: For therapeutic doses with evidence-supported effects, use enhanced curcumin formulation supplements. Use turmeric powder in cooking as part of anti-inflammatory diet pattern. Both can be done together. Safety of high-dose turmeric powder: Multiple grams daily of turmeric powder may cause GI upset, increase oxalate intake (kidney stone concern in susceptible individuals), and have variable heavy metal content depending on source. Supplements with third-party testing have more reliable safety profile.
How does curcumin fit into a longevity protocol?
Curcumin is a core component of most evidence-based longevity protocols due to its pleiotropic mechanisms addressing multiple aging hallmarks. Mechanistic rationale for longevity applications: (1) Chronic inflammation reduction (NF-κB, cytokines) — inflammation is a major driver of aging-related decline (inflammaging); (2) Oxidative stress mitigation (Nrf2 activation, direct antioxidant) — oxidative damage accumulates across the aging process; (3) AMPK activation — shared with metformin and berberine; cellular energy sensor associated with healthspan; (4) mTOR modulation — shared with rapamycin; promotes autophagy; (5) Mitochondrial support — PGC-1α upregulation for mitochondrial biogenesis; (6) Epigenetic effects — DNMT/HDAC modulation; (7) Senescence effects — emerging evidence curcumin has some senolytic activity; (8) Gut microbiome modulation — favorable shifts in microbiome composition. Integration in longevity stack: Curcumin 500 mg/day (Meriva, Theracurmin, or Longvida for different emphasis) combined with: NMN 500-1000 mg/day (NAD+ precursor); Berberine 500 mg BID (AMPK activator, metabolic); NAC 600 mg BID (glutathione support); CoQ10 Ubiquinol 100-200 mg (mitochondrial); Rapamycin weekly (mTORC1 inhibition, physician-supervised); Omega-3 EPA/DHA 2-4 g/day (anti-inflammatory); Vitamin D 4000-6000 IU/day; Vitamin K2 MK-7 100-200 mcg/day; Magnesium Glycinate 400-600 mg/day; Creatine 5 g/day (muscle/brain support); B-complex methylated. Lifestyle foundation (more important than any supplement): Regular resistance training (2-3x/week); aerobic exercise (150+ min/week moderate or 75+ min vigorous); adequate sleep (7-9 hours); Mediterranean/low-glycemic diet; social engagement; stress management; cognitive engagement; avoidance of smoking/excessive alcohol. Evidence quality for longevity effects: Strong mechanistic data; moderate evidence for disease prevention endpoints (diabetes prevention, NAFLD, cardiovascular risk factors); limited evidence for hard longevity endpoints (hasn't been proven to extend human lifespan in RCTs). The healthspan framework is more defensible than the lifespan-extension claim. Target populations who may benefit most: Adults >40 with elevated inflammatory markers (hs-CRP >2); adults with multiple metabolic risk factors; adults with family history of early cardiovascular or neurodegenerative disease; adults already optimizing lifestyle and seeking addition of evidence-supported interventions. Cost-benefit: Enhanced curcumin formulation ($25-40/month for Meriva or equivalent) is reasonable investment for the evidence base. Much of the benefit may come from earlier intervention (40s-60s) rather than waiting until established disease. Monitoring: Annual hs-CRP, lipid panel, HbA1c, CMP; periodic review of ongoing rationale; lifestyle adherence assessment. Bottom line: Curcumin is one of the more mechanistically-supported and evidence-based components of longevity-oriented supplementation. It is best viewed as a component of multifactorial healthspan strategy rather than a standalone anti-aging intervention. The combination of lifestyle foundation + targeted evidence-based supplementation + appropriate medical care is the realistic model for health-span optimization.
Research Tools
Related Compounds
View AllSide-by-Side Comparisons
All ComparisonsCompare Curcumin head-to-head: mechanism, half-life, dosing, safety, and live pricing.
Free 2026 Peptide Cheat Sheet — 50 pages, PDF
Dosing, reconstitution, stacks, half-lives, and vendor trust tiers. The reference we wish we had on day one.
